Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Ana M. Aparicio, Axel Heidenreich, Shahneen Sandhu, Yiran Zhang, Mark Salvati, Aditya Shetty, Nooshin Hashemi Sadraei (2021). Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).. , 39(15_suppl), DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.tps5100.
